Aprea Therapeutics, Inc. (NASDAQ:APRE) Stock Rated “Moderate Buy” by Wall Street Brokerages

Aprea Therapeutics, Inc. (NASDAQ:APRE) has earned a consensus rating of “Moderate Buy” from the six brokerages that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $2.80.

Several research firms have weighed in on APRE. LADENBURG THALM/SH SH began coverage on Aprea Therapeutics in a report on Wednesday, October 14th. They set a “buy” rating and a $2.00 target price on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Aprea Therapeutics in a research report on Thursday, October 15th. Finally, Wedbush dropped their price objective on shares of Aprea Therapeutics to $3.00 and set an “outperform” rating on the stock in a report on Thursday, August 13th.

Aprea Therapeutics Price Performance

Shares of APRE stock opened at $0.56 on Wednesday. Aprea Therapeutics has a 12-month low of $0.51 and a 12-month high of $1.64. The business has a 50 day simple moving average of $0.72 and a 200 day simple moving average of $0.76.

Aprea Therapeutics (NASDAQ:APRE) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.11. Equities research analysts anticipate that Aprea Therapeutics will post -0.36 EPS for the current year.

Hedge Funds Weigh In On Aprea Therapeutics

An institutional investor recently raised its position in Aprea Therapeutics stock. AIGH Capital Management LLC boosted its stake in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) by 174.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,015,541 shares of the company’s stock after acquiring an additional 645,000 shares during the quarter. AIGH Capital Management LLC owned 8.47% of Aprea Therapeutics worth $775,000 as of its most recent SEC filing. 34.19% of the stock is currently owned by institutional investors and hedge funds.

About Aprea Therapeutics

Aprea Therapeutics, Inc (NASDAQ: APRE) is a clinical-stage biopharmaceutical company developing targeted therapies for cancer. Its research focuses on treatments designed to exploit weaknesses in tumor cells, with an emphasis on DNA damage response and cell-cycle regulation.

The company’s lead investigational program is ATRN-119, an oral, selective inhibitor of ataxia telangiectasia and Rad3-related protein, or ATR. ATRN-119 is being evaluated in early-stage clinical studies for patients with advanced solid tumors.